CommercialCoverageMedium impact
Electromagnetic and Pulsed Field Stimulation 1.01.59
Excellus BlueCross BlueShield·Pain Management, PM&R (Physical Medicine & Rehab), Orthopedics +1 more·Durable Medical Equipment & Supplies
Effective date
May 21, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has classified several electromagnetic and pulsed field stimulation therapies as investigational and non-covered, including peripheral magnetic stimulation for chronic neuropathic pain, pulsed electrical stimulation for arthritis, and targeted electromagnetic field stimulation devices. Claims for these services will likely be denied as experimental.
Action Required
Before May 21, 2026: Billing team must identify and flag claims for electromagnetic and pulsed field stimulation devices including Axon Therapy, MagVenture Pain Therapy, BioniCare, MedRelief ST Series, Jstim1000, SofPulse, and OrthoCor Active Knee System as investigational. Update denial management procedures to expect denials for these services. Notify providers that these treatments are considered experimental by Excellus and should not be recommended for Excellus members without patient understanding of non-coverage.